文献速递肿瘤 PET/CT放射性药物与辐射防护

89Zr-去铁胺-贝马利单抗(靶向共同淋巴管内皮和血管内皮受体-1的人源化抗体)在兔肾纤维化模型中的临床前评价

Preclinical Evaluation of 89Zr-Desferrioxamine-Bexmarilimab, a Humanized Antibody Against Common Lymphatic Endothelial and Vascular Endothelial Receptor-1, in a Rabbit Model of Renal Fibrosis.
PubMed 文献 · J Nucl Med · 2022-10-27

本研究将靶向CLEVER-1的人源化单克隆抗体贝马利单抗与去铁胺偶联并用89Zr标记,在单侧输尿管梗阻所致兔肾纤维化模型中评价其分布动力学与体内稳定性。结果显示89Zr-DFO-贝马利单抗从血循环快速清除并分布至肝脾,注射后24小时纤维化肾皮质摄取显著高于对侧或健康肾;70 kg成人估算有效剂量为0.70 mSv/MBq。结论支持未来开展人体PET研究。

要点

  • 89Zr-DFO-贝马利单抗在兔肾纤维化模型中从血循环快速清除并分布至肝脾。
  • 注射后24小时纤维化肾皮质摄取显著高于对侧或健康肾,该区域富含CLEVER-1阳性细胞。
  • 70 kg成人估算有效剂量为0.70 mSv/MBq,支持未来人体PET研究。

核心结论

  • 89Zr-DFO-贝马利单抗的特性支持未来开展人体PET研究,例如用于对贝马利单抗治疗患者进行分层、评估治疗疗效或监测疾病进展。

研究设计与样本

  • 贝马利单抗与去铁胺(DFO)偶联并用89Zr标记,经流式细胞术确认免疫反应性保留。
  • 在单侧输尿管梗阻介导的兔肾纤维化模型中,静脉给予89Zr-DFO-贝马利单抗(0.1 mg/kg),测定长达7天的分布动力学。
  • 采用十二烷基硫酸钠-聚丙烯酰胺凝胶电泳联合放射自显影评估89Zr-DFO-贝马利单抗的体内稳定性,并基于健康兔数据估算人体辐射剂量。

主要发现

  • 89Zr-DFO-贝马利单抗从血循环快速清除并分布至肝脾。
  • 注射后24小时,PET/CT、离体γ计数和放射自显影显示单侧输尿管梗阻手术所致纤维化肾皮质对89Zr-DFO-贝马利单抗的摄取显著高于对侧或健康肾。
  • 纤维化肾皮质以丰富的CLEVER-1阳性细胞为特征。
  • 70 kg成人估算有效剂量为0.70 mSv/MBq。

关键数值与推荐

  • 静脉给药剂量为0.1 mg/kg。
  • 70 kg成人估算有效剂量为0.70 mSv/MBq。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bexmarilimab is a new humanized monoclonal antibody against common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and is in clinical trials for macrophage-guided cancer immunotherapy. In addition being associated with cancer, CLEVER-1 is also associated with fibrosis. To facilitate prospective human PET studies, we preclinically evaluated 89Zr-labeled bexmarilimab in rabbits. Methods: Bexmarilimab was conjugated with desferrioxamine (DFO) and radiolabeled with 89Zr. Retained immunoreactivity was confirmed by flow cytometry. The distribution kinetics of intravenously administered 89Zr-DFO-bexmarilimab (0.1 mg/kg) were determined for up to 7 d in a rabbit model of renal fibrosis mediated by unilateral ureteric obstruction. The in vivo stability of 89Zr-DFO-bexmarilimab was evaluated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis in combination with autoradiography. Additionally, we estimated the human radiation dose from data obtained in healthy rabbits. Results: 89Zr-DFO-bexmarilimab cleared rapidly from the blood circulation and distributed to the liver and spleen. At 24 h after injection, PET/CT, ex vivo γ-counting, and autoradiography demonstrated that there was significantly higher 89Zr-DFO-bexmarilimab uptake in unilateral ureteric obstruction-operated fibrotic renal cortex, characterized by abundant CLEVER-1-positive cells, than in contralateral or healthy kidneys. The estimated effective dose for a 70-kg human was 0.70 mSv/MBq. Conclusion: The characteristics of 89Zr-DFO-bexmarilimab support future human PET studies to, for example, stratify patients for bexmarilimab treatment, evaluate the efficacy of treatment, or monitor disease progression.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Moisio O, Virta J, Yatkin E, et al. Preclinical Evaluation of 89Zr-Desferrioxamine-Bexmarilimab, a Humanized Antibody Against Common Lymphatic Endothelial and Vascular Endothelial Receptor-1, in a Rabbit Model of Renal Fibrosis. J Nucl Med. 2022. PMID: 36302655. doi:10.2967/jnumed.122.264725

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。